Pharma BD Deal Intelligence
Eisai Co., Ltd. acquired MGI Pharma Inc. for approximately $3.9 billion ($41.00 per share in an all-cash tender offer, a ~23% premium to MGI's pre-announcement close). The transaction added MGI's marketed oncology and supportive-care franchise—Aloxi (palonosetron) for chemotherapy-induced nausea and vomiting and Dacogen (decitabine) for myelodysplastic syndromes—expanding Eisai's U.S. oncology and acute-care presence as it faced looming patent expiry on its CNS franchise. The tender offer was completed on January 28, 2008, making MGI Pharma a wholly owned Eisai subsidiary.